Literature DB >> 12089387

Familial risk of preeclampsia in Newfoundland: a population-based study.

Lesa M Dawson1, Patrick S Parfrey, Donna Hefferton, Elizabeth L Dicks, M Jim Cooper, David Young, Philip A Marsden.   

Abstract

This study sought to quantify the familial risk of preeclampsia (proteinuric hypertension) in Newfoundland and to identify characteristics in probands that predict increased familial risk. Reviewed were 5173 obstetric charts from 10 hospitals, representing 99% of deliveries on the island of Newfoundland for a 1-yr period from April 1996 to March 1997; pregnancy-induced hypertension was diagnosed according to strict criteria. Family obstetric histories were obtained from identified probands with preeclampsia, and sisters and mothers of probands were interviewed. In addition, the obstetric charts from sisters and mothers were reviewed to identify preeclampsia. The incidence of preeclampsia in the population was 5.6% (n = 292), and in primiparous women it was 7.9%. Factors independently associated with increased risk of preeclampsia included primiparous delivery, multiple gestation, pregestational and gestational diabetes, maternal age of more than 35 yr, and region of the province. Of 330 sisters identified, 217 had 445 pregnancies, with 331 charts located for review. The incidence of preeclampsia (based on chart review) in 163 primiparous sisters was 20.2%. The relative risk of preeclampsia in primiparous sisters of probands with preeclampsia compared with primiparous women in the population was 2.6 (95% confidence interval, 1.8 to 3.6). Factors in probands independently associated with a higher risk of preeclampsia in sisters included at least 2+ proteinuria and region of the province. This population-based study, which used unbiased ascertainment and strict diagnostic criteria, demonstrated a significantly higher risk of preeclampsia in sisters of probands with preeclampsia, particularly when probands were defined by severity of preeclampsia and by geographic region.

Entities:  

Mesh:

Year:  2002        PMID: 12089387     DOI: 10.1097/01.asn.0000017224.24670.82

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

Review 1.  Preeclampsia: theories and speculations.

Authors:  Jeffrey C Livingston; Bryan D Maxwell
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

2.  Maternal ethnicity and pre-eclampsia in New York City, 1995-2003.

Authors:  Jian Gong; David A Savitz; Cheryl R Stein; Stephanie M Engel
Journal:  Paediatr Perinat Epidemiol       Date:  2011-08-01       Impact factor: 3.980

3.  Methods for dealing with discrepant records in linked population health datasets: a cross-sectional study.

Authors:  Christine L Roberts; Charles S Algert; Jane B Ford
Journal:  BMC Health Serv Res       Date:  2007-01-30       Impact factor: 2.655

4.  Risk factors for hypertensive disorders of pregnancy among mothers in Tigray region, Ethiopia: matched case-control study.

Authors:  Hailemariam Berhe Kahsay; Fikre Enquselassie Gashe; Wubegzier Mekonnen Ayele
Journal:  BMC Pregnancy Childbirth       Date:  2018-12-06       Impact factor: 3.007

5.  The accuracy of reporting of the hypertensive disorders of pregnancy in population health data.

Authors:  Christine L Roberts; Jane C Bell; Jane B Ford; Ruth M Hadfield; Charles S Algert; Jonathan M Morris
Journal:  Hypertens Pregnancy       Date:  2008       Impact factor: 2.108

6.  Population-based estimate of sibling risk for preterm birth, preterm premature rupture of membranes, placental abruption and pre-eclampsia.

Authors:  Jevon Plunkett; Ingrid Borecki; Thomas Morgan; David Stamilio; Louis J Muglia
Journal:  BMC Genet       Date:  2008-07-08       Impact factor: 2.797

Review 7.  Pregnancy, parturition and preeclampsia in women of African ancestry.

Authors:  Annettee Nakimuli; Olympe Chazara; Josaphat Byamugisha; Alison M Elliott; Pontiano Kaleebu; Florence Mirembe; Ashley Moffett
Journal:  Am J Obstet Gynecol       Date:  2013-10-30       Impact factor: 8.661

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.